PVALB Was Identified as an Independent Prognostic Factor for HCC Closely Related to Immunity, and Its Absence Accelerates Tumor Progression by Regulating NK Cell Infiltration
DOI: https://doi.org/10.2147/jhc.s450479
2024-05-08
Journal of Hepatocellular Carcinoma
Abstract:Yiyang Gong, 1, 2, &ast Minqin Zhou, 2, &ast Yanting Zhu, 2, &ast Jingying Pan, 2 Xuanrui Zhou, 2 Yike Jiang, 2 Hong Zeng, 2 Hao Zheng, 2 Xitong Geng, 2 Da Huang 1 1 Department of Thyroid Surgery; Second Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China; 2 Second College of Clinical Medicine, Nanchang University, Nanchang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Da Huang, Department of Thyroid Surgery, Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang, Jiangxi Province, 330000, People's Republic of China, Tel +13576113993, Email Purpose: Hepatocellular carcinoma is the most common primary liver cancer, with poor prognosis. Complex immune microenvironment of the liver is linked to the development of HCC. PVALB is a calcium-binding protein which has been described as a cancer suppressor gene in thyroid cancer and glioma. Nevertheless, the role of PVALB in HCC is unknown. Materials and Methods: We obtained data from TCGA and GSE54236 datasets. MCP-counter, WGCNA and LASSO model were applied to identify PVALB. With UALCAN, MethSurv, and other websites, we probed the expression, methylation and survival of PVALB. LinkedOmics and GSEA were adopted for functional analysis, while TIMER, TISIDB, Kaplan-Meier plotter, TIDE databases were utilized to evaluate the relevance of PVALB to the tumor immune microenvironment and predict immunotherapy efficacy. TargetScan, DIANA, LncRNASNP2 databases and relevant experiments were employed to construct ceRNA network. Finally, molecular docking and drug sensitivity of PVALB were characterized by GeneMANIA, CTD, and so on. Results: PVALB was recognized as a gene associated with HCC and NK cell. Its expression was down-regulated in HCC tissue, which lead to adverse prognosis. Besides, the hypomethylation of PVALB was related to its reduced expression. Notably, PVALB was tightly linked to immune, and its reduced expression attenuated the anticancer effect of NK cells via the Fas/FasL pathway, leading to a adverse outcome. The lnc-YY1AP1-3/hsa-miR-6735-5p/PVALB axis may regulate the PVALB expression. Finally, we found immunotherapy might be a viable treatment option. Conclusion: In a word, PVALB is a prognostic indicator, whose low expression facilitates HCC progression by impacting NK cell infiltration. Keywords: PVALB, hepatocellular carcinoma, immune, ceRNA, bioinformatics, prognostic factor Hepatocellular carcinoma (HCC) is the fifth most frequent cancer worldwide, occupying approximately 90% of primary liver cancer, 1 while it is also a leading cause of death related to major cancers globally. 2 In contrast to the observed reduction in mortality from all other common cancers (eg, breast, lung, and prostate), the death rate from HCC continually increases by 2–3% each year. 3 According to current studies, chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, and non-alcoholic fatty liver disease (NAFLD) are the most prominent risk factors for HCC. 4 In recent years, tumor markers have displayed superior clinical value in assisting the diagnosis of malignant tumors, and among them, serum alpha-fetoprotein (AFP) has been the most prevalent and essential indicator for detecting HCC and monitoring the therapeutic efficacy. However, despite its overall specificity for predicting HCC as high as 80% to 94%, the sensitivity is only 25% to 65%, and there still exists a controversy about the specific threshold of AFP for survival or recurrence. 5 Also, as a typical tumor related to inflammation, HCC is characterized by immune evasion during the process of development and evolution, 6 which is mediated by the accumulation of immunosuppressive cells in the tumor and the activation of multiple inhibitory receptor-ligand pathways. 7 Hence, it is imperative to explore alternative biomarkers for diagnosing and predicting the effectiveness of HCC treatment, while also impeding immune evasion. The Parvalbumin (PVALB) gene is positioned on the long arm of chromosome 22 (22q13), 8 which encodes a protein belongs to the EF-hand protein superfamily, and depicted as a Ca2+ buffering protein. 9,10 Proteins of this family exhibit a conserved helix-loop-helix structural motif, and their combined functions encompass the modulation of numerous vital cellular processes such as gene transcription, protein phosphorylation, nucleotide metabolism, and ion transport. 11–13 Under normal conditions, as a calci -Abstract Truncated-
oncology